Glesatinib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameGlesatinib
Drug Alias Nameglesatinib格来替尼glesatinibumMGCD-265MG-90265X +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsProtein-tyrosine kinases inhibitorsAXL receptor tyrosine kinase inhibitors +[8] 
TargetsHepatocyte growth factor receptorProtein-tyrosine kinasesAXL receptor tyrosine kinase +[8] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMirati Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMirati Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A